Payment overview · 2025
General Payments
$1,147.29
36 reported records · 13 companies
Healthcare provider profile · identity verified
Fadi H Sayegh, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRONX, NY · NPI 1447647607
Verified facts
What the public records show
CMS Open Payments records show Fadi H Sayegh, MD received $1,147.29 in general payments during 2025 across 36 reported records.
Novo Nordisk Inc accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $375.13 | 32.7% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $250.00 | 21.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $118.38 | 10.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $96.01 | 8.4% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $61.72 | 5.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.70 | 4.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.90 | 4.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.47 | 2.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.44 | 2.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.42 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.33 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.65 | 1.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.14 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,132.66 | 35 |
| Education | $14.63 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $375.13 | 15 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $375.13 | 15 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $118.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $96.01 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $78.12 | 4 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $61.72 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $61.72 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.90 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.90 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $30.47 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 682 | 177 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 113 |
| Metformin Hcl | Metformin Hcl | 301 | 73 |
| Losartan Potassium | Losartan Potassium | 182 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 177 | 44 |
| Memantine Hcl | Memantine Hcl | 173 | 24 |
| Lisinopril | Lisinopril | 170 | 52 |
| Eliquis | Apixaban | 161 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 36 |
| Gabapentin | Gabapentin | 128 | 43 |
| Mirtazapine | Mirtazapine | 125 | 20 |
| Sertraline Hcl | Sertraline Hcl | 118 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 41 |
| Furosemide | Furosemide | 107 | 19 |
| Clonazepam | Clonazepam | 104 | 11 |
| Divalproex Sodium | Divalproex Sodium | 103 | suppressed |
| Nifedipine Er | Nifedipine | 103 | 17 |
| Omeprazole | Omeprazole | 98 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 34 |
| Simvastatin | Simvastatin | 77 | 20 |
| Haloperidol | Haloperidol | 76 | suppressed |
| Risperidone | Risperidone | 76 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 15 |
| Olanzapine | Olanzapine | 73 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 72 | suppressed |
| Jardiance | Empagliflozin | 71 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 67 | 13 |
| Levetiracetam | Levetiracetam | 67 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 67 | suppressed |
| Latanoprost | Latanoprost | 64 | 16 |
| Xarelto | Rivaroxaban | 61 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 17 |
| Januvia | Sitagliptin Phosphate | 60 | 12 |
| Famotidine | Famotidine | 58 | 24 |
| Prednisone | Prednisone | 55 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 52 | 17 |
| Trazodone Hcl | Trazodone Hcl | 52 | suppressed |
| Carvedilol | Carvedilol | 50 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 47 | suppressed |
| Ezetimibe | Ezetimibe | 46 | 15 |
| Atenolol | Atenolol | 45 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 45 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | 12 |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 19 |
| Ozempic | Semaglutide | 37 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 11 |
| Alendronate Sodium | Alendronate Sodium | 35 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 11 |
| Carbamazepine | Carbamazepine | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Insulin Lispro | Insulin Lispro | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Topiramate | Topiramate | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 29 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Rexulti | Brexpiprazole | 28 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 11 |
| Azithromycin | Azithromycin | 25 | 22 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 25 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 17 |
| Allopurinol | Allopurinol | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Humira | Adalimumab | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 11 |
| Nystatin | Nystatin | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Risperidone Er | Risperidone Microspheres | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,147.29 · 36 records | Novo Nordisk Inc | ARISTADA, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, KRYSTEXXA, LYBALVI, MOUNJARO, Ozempic, REXULTI, Rybelsus, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error